Cadrenal Therapeutics to Join Lytham Partners Spring 2024 Investor Conference on May 30

Cadrenal Therapeutics, Inc., a biopharmaceutical company listed on Nasdaq under the ticker CVKD, is actively developing a promising anticoagulant named tecarfarin. This medication is designed to mitigate the risk of heart attacks, strokes, and fatalities caused by blood clots, especially in patients with rare cardiovascular conditions. The company is preparing to showcase its progress at the Lytham Partners Spring 2024 Investor Conference, an online event scheduled for Thursday, May 30, 2024. During this conference, Cadrenal Therapeutics will deliver a webcasted presentation and engage in one-on-one meetings with investors.

The webcast presentation is slated for 12:30 PM Eastern Time on the specified date. Interested parties can access the live stream through the conference homepage. For those unable to attend the live session, a replay will be available following the event.

In addition to the presentation, Cadrenal Therapeutics' management team will hold virtual one-on-one meetings with investors throughout the day. To schedule a meeting, investors need to contact Lytham Partners via email or register through the event’s platform.

Cadrenal Therapeutics is focused on addressing unmet needs in the field of anticoagulation therapy through the development of tecarfarin. This novel oral anticoagulant is in the late stages of clinical development and is designed to offer a reversible mechanism of action. Unlike traditional anticoagulants like warfarin, tecarfarin utilizes a different metabolic pathway, potentially offering a safer alternative for patients requiring chronic anticoagulation.

The U.S. Food and Drug Administration (FDA) has granted tecarfarin orphan drug and fast-track designations for preventing systemic thromboembolism, particularly in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Furthermore, tecarfarin has received an orphan drug designation for preventing thrombosis and thromboembolism in patients with ventricular assist devices (VADs). Cadrenal Therapeutics is also exploring additional regulatory pathways to address other unmet needs, such as thrombotic antiphospholipid syndrome (APS).

Tecarfarin has undergone extensive clinical evaluation, with eleven human trials involving more than 1,000 participants. Results from Phase 1, Phase 2, and Phase 2/3 trials indicate that tecarfarin is generally well-tolerated among both healthy adults and patients with chronic kidney disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!